tradingkey.logo
๎™

Alaunos Therapeutics Inc

TCRT
๎˜น
์ƒ์„ธ ์ฐจํŠธ ๋ณด๊ธฐ
3.560USD
-0.420-10.55%
์ข…๊ฐ€ย 12/19, 16:00๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
7.85M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM
๎™

Alaunos Therapeutics Inc

3.560
-0.420-10.55%
Intraday
1m
30m
1h
D
W
M
D

์˜ค๋Š˜

-10.55%

5์ผ

-16.43%

1๊ฐœ์›”

+0.28%

6๊ฐœ์›”

-17.02%

์˜ฌํ•ด ํ˜„์žฌ๊นŒ์ง€

+86.88%

1๋…„

+81.63%

์ƒ์„ธ ์ฐจํŠธ ๋ณด๊ธฐ

TradingKey Alaunos Therapeutics Inc ์ฃผ์‹ ์ ์ˆ˜๎˜

ํ†ตํ™”: USD ๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: 2025-12-19

์ฃผ์š” ์ธ์‚ฌ์ดํŠธ

Alaunos Therapeutics Inc์˜ ํŽ€๋”๋ฉ˜ํ„ธ์€ ๋น„๊ต์  ์•ˆ์ •์  ์ƒํƒœ์ด๋ฉฐ, ์„ฑ์žฅ ์ž ์žฌ๋ ฅ์€ ๋†’์Šต๋‹ˆ๋‹ค.๊ธฐ์—…์˜ ๋ฐธ๋ฅ˜์—์ด์…˜์€ ์ ์ •ํ•˜๊ฒŒ ํ‰๊ฐ€๋œ ๊ฒƒ์œผ๋กœ ๊ฐ„์ฃผ๋˜๋ฉฐ, ์ƒ๋ช…๊ณตํ•™ ๋ฐ ์˜๋ฃŒ ์—ฐ๊ตฌ ์‚ฐ์—… ๋‚ด ๋žญํ‚น์€ 229/404์œ„์ž…๋‹ˆ๋‹ค.๊ธฐ๊ด€ ๋ณด์œ  ๋น„์œจ์€ ๋งค์šฐ ๋†’์€.์ค‘๊ธฐ์ ์œผ๋กœ ์ฃผ๊ฐ€๋Š” ์ƒ์Šน ์ถ”์„ธ์ผ ๊ฒƒ์œผ๋กœ ์˜ˆ์ƒ๋ฉ๋‹ˆ๋‹ค.์ง€๋‚œ ํ•œ ๋‹ฌ๊ฐ„ ์ฃผ์‹ ์‹œ์žฅ์—์„œ ์–‘ํ˜ธํ•œ ์„ฑ๊ณผ๋ฅผ ๊ฑฐ๋‘๊ณ  ํŽ€๋”๋ฉ˜ํ„ธ์ด ์šฐ์ˆ˜ํ–ˆ์ง€๋งŒ, ๊ธฐ์ˆ ์  ์ง€ํ‘œ๊ฐ€ ํ˜„์žฌ์˜ ์ถ”์„ธ๋ฅผ ๋’ท๋ฐ›์นจํ•˜์ง€ ๋ชปํ•˜๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค.์ฃผ๊ฐ€๋Š” ์ง€์ง€์„ ๊ณผ ์ €ํ•ญ์„  ์‚ฌ์ด์—์„œ ํšก๋ณดํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ๋ฒ”์œ„ ๋งค๋งค ๊ธฐ๋ฐ˜์˜ ์Šค์œ™ ํŠธ๋ ˆ์ด๋”ฉ์— ์ ํ•ฉํ•œ ์ƒํ™ฉ์ž…๋‹ˆ๋‹ค.

Alaunos Therapeutics Inc ์ ์ˆ˜๎˜ฐ๎˜ฐ

๊ด€๋ จ ์ •๋ณด

์‚ฐ์—… ์ˆœ์œ„
229 / 404
์ „์ฒด ์ˆœ์œ„
483 / 4582
์‚ฐ์—…
์ƒ๋ช…๊ณตํ•™ ๋ฐ ์˜๋ฃŒ ์—ฐ๊ตฌ

์ €ํ•ญ์„  & ์ง€์ง€์„ 

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

๋ ˆ์ด๋” ์ฐจํŠธ

ํ˜„์žฌ ๊ฐ€๊ฒฉ
๊ณผ๊ฑฐ

๋ถ„์„๊ฐ€ ๋ชฉํ‘œ๊ฐ€

0 ๋ช…์˜ ๋ถ„์„๊ฐ€๋ฅผ ๊ธฐ์ค€์œผ๋กœ
--
ํ˜„์žฌ ๋“ฑ๊ธ‰
0.000
๋ชฉํ‘œ ๊ฐ€๊ฒฉ
0.00%
์ƒ์Šน ์—ฌ๋ ฅ
๋ฉด์ฑ… ์กฐํ•ญ: ์• ๋„๋ฆฌ์ŠคํŠธ ํ‰๊ฐ€ ๋ฐ ๋ชฉํ‘œ ์ฃผ๊ฐ€๋Š” ์ •๋ณด ์ œ๊ณต์„ ์œ„ํ•œ ๋ชฉ์ ์œผ๋กœ LSEG์—์„œ ์ œ๊ณต๋˜๋ฉฐ, ํˆฌ์ž ์กฐ์–ธ์œผ๋กœ ๊ฐ„์ฃผ๋˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.

Alaunos Therapeutics Inc ์ฃผ์š” ๋‚ด์šฉ

๊ฐ•์ ์œ„ํ—˜ ์š”์†Œ
Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Companyโ€™s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.
์„ฑ์žฅ ์ค‘
ํšŒ์‚ฌ๋Š” ์„ฑ์žฅ ๋‹จ๊ณ„์— ์žˆ์œผ๋ฉฐ, ์ตœ์‹  ์—ฐ๊ฐ„ ์ˆ˜์ต์€ ๋ฏธํ™” 10.00K์— ๋‹ฌํ•ฉ๋‹ˆ๋‹ค.
๊ณผ์†Œ ํ‰๊ฐ€๋œ
ํšŒ์‚ฌ์˜ ์ตœ์‹  PE์€ -1.57๋กœ, ์ตœ๊ทผ 3๋…„ ๊ธฐ์ค€ ๋‚ฎ์€ ๋ฐฑ๋ถ„์œ„ ๋ฒ”์œ„์— ์†ํ•ฉ๋‹ˆ๋‹ค.
๊ธฐ๊ด€ ๋งค๋„
์ตœ์‹  ๊ธฐ๊ด€ ๋ณด์œ  ์ฃผ์‹ ์ˆ˜๋Š” 104.76K์ฃผ์ด๋ฉฐ, ์ „ ๋ถ„๊ธฐ ๋Œ€๋น„ 59.27% ๊ฐ์†Œํ–ˆ์Šต๋‹ˆ๋‹ค.
CI Select Canadian Equity Fund๊ฐ€ ๋ณด์œ 
์Šคํƒ€ ํˆฌ์ž์ž CI Select Canadian Equity Fund์ด(๊ฐ€) ์ด ์ฃผ์‹ 23.00์ฃผ๋ฅผ ๋ณด์œ ํ•˜๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค.
์‹œ์žฅ ํ™œ๋™ ์ฆ๊ฐ€
ํšŒ์‚ฌ๋Š” ํˆฌ์ž์ž๋“ค์˜ ๊ด€์‹ฌ์ด ๋†’์•„์ ธ, ์ตœ๊ทผ 20์ผ๊ฐ„ ํšŒ์ „์œจ์ด -0.64์ž…๋‹ˆ๋‹ค.

Alaunos Therapeutics Inc ๋‰ด์Šค

๋” ๋งŽ์€ ๋‰ด์Šค๊ฐ€ ๊ณง ์—…๋ฐ์ดํŠธ๋ฉ๋‹ˆ๋‹ค. ๊ณ„์† ์ง€์ผœ๋ด ์ฃผ์„ธ์š”โ€ฆ

์žฌ๋ฌด ์ง€ํ‘œ๎˜

EPS

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

์ด ์ˆ˜์ต

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

Alaunos Therapeutics Inc ์ •๋ณด๎˜

Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Companyโ€™s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.
์ข…๋ชฉ ์ฝ”๋“œ TCRT
ํšŒ์‚ฌAlaunos Therapeutics Inc
CEOWeis (Holger)
์›น์‚ฌ์ดํŠธhttps://alaunos.com/

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Alaunos Therapeutics Inc(TCRT)์˜ ํ˜„์žฌ ๊ฐ€๊ฒฉ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Alaunos Therapeutics Inc(TCRT)์˜ ํ˜„์žฌ ์ฃผ๊ฐ€๋Š” 3.560์ž…๋‹ˆ๋‹ค.

Alaunos Therapeutics Inc์˜ ์ข…๋ชฉ ๊ธฐํ˜ธ(Symbol)๋Š” ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
Alaunos Therapeutics Inc์˜ ์ข…๋ชฉ ์ฝ”๋“œ๋Š” TCRT์ž…๋‹ˆ๋‹ค.

Alaunos Therapeutics Inc์˜ 52์ฃผ ์ตœ๊ณ ๊ฐ€๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Alaunos Therapeutics Inc์˜ 52์ฃผ ์ตœ๊ณ ๊ฐ€๋Š” 6.200์ž…๋‹ˆ๋‹ค.

Alaunos Therapeutics Inc์˜ 52์ฃผ ์ตœ์ €๊ฐ€๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Alaunos Therapeutics Inc์˜ 52์ฃผ ์ตœ์ €๊ฐ€๋Š” 1.314์ž…๋‹ˆ๋‹ค.

Alaunos Therapeutics Inc์˜ ์‹œ๊ฐ€์ด์•ก์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Alaunos Therapeutics Inc์˜ ์‹œ๊ฐ€์ด์•ก์€ 7.85M์ž…๋‹ˆ๋‹ค.

Alaunos Therapeutics Inc์˜ ์ˆœ์ด์ต์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Alaunos Therapeutics Inc์˜ ์ˆœ์ด์ต์€ -4.68M์ž…๋‹ˆ๋‹ค.

Alaunos Therapeutics Inc(TCRT)์˜ ํ˜„์žฌ ํˆฌ์ž ๋“ฑ๊ธ‰์€ ๋งค์ˆ˜, ๋ณด์œ , ๋งค๋„ ์ค‘ ์–ด๋–ค๊ฐ€์š”?

๎™Œ
์• ๋„๋ฆฌ์ŠคํŠธ๋“ค์— ๋”ฐ๋ฅด๋ฉด, Alaunos Therapeutics Inc(TCRT)๋Š” ์ „๋ฐ˜์ ์ธ ํ‰๊ฐ€์—์„œ -- ๋“ฑ๊ธ‰์„ ๋ฐ›๊ณ  ์žˆ์œผ๋ฉฐ, ๋ชฉํ‘œ ์ฃผ๊ฐ€๋Š” --์ž…๋‹ˆ๋‹ค.

Alaunos Therapeutics Inc(TCRT)์˜ ์ฃผ๋‹น์ˆœ์ด์ต(EPS TTM)์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Alaunos Therapeutics Inc(TCRT)์˜ ์ฃผ๋‹น์ˆœ์ด์ต(EPS TTM)์€ -2.265์ž…๋‹ˆ๋‹ค.
KeyAI
๎™